ADC Therapeutics gibt erste Ergebnisse der von Prufarzten initiierten klinischen Phase-II-Studie zur Bewertung von ZYNLONTA(r) in Kombination mit Rituximab b

Source :: Plus Company Updates. December 14, 2023
Publication Year :: 2023
Abstract: LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase II clinical trial evaluating ZYNLONTA(r) (Loncastuximab-tesirine-Lpyl) in [...]

Subjects :: ADC Therapeutics S.A. -- Product development
Lymphomas
Clinical trials
Bendamustine
General interest
News, opinion and commentary

Tools